P-123 Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study

2% of assessments.Regarding OSDI, from 186/217/181 responses received, the number of "all/most' of the time worst responses in the ocular symptoms category were 5 (3%)/6 (3%)/8 (4%), while the respective proportions in the ADL category were 6 (3%)/4 (2%)/3 (2%).In terms of missed doses, among 122/129/112 planned belamaf infusions across cohorts, the number of skipped doses due to OAEs were 48 (39%)/41 (32%)/30 (27%).The overall response rate was 100%, no disease progression was observed over a median follow-up of 18.7 months, and 29 (81%) patients achieved at least VGPR while 15 (42%) achieved at least CR, with a median time to first response of 1 month.Conclusions: Belamaf-Rd, with the extended schedule for belamaf, had a minimal impact in visionrelated functioning, as the 'all/most' of the time worst answers in the ADL category of OSDI was < 3% across cohorts.Furthermore, the frequency of clinically relevant impairment in vision was low, as a meaningful BCVA decline was observed in ≤10% of assessments, with a rapid time to resolution.Finally, the treatment combination induced rapid, deep and durable responses across all dose levels.In conclusion, this novel extended belamaf schedule nearly eradicates the risk for clinically relevant ocular toxicity and impact on ADL, without any compromise in clinical activity.